115 related articles for article (PubMed ID: 34271301)
1. Cytarabine and EIP co-administration synergistically reduces viability of acute lymphoblastic leukemia cells with high ERG expression.
Cheng L; Zeng S; Yan D; Tu L; Yang Y; Wang X; Zheng X
Leuk Res; 2021 Oct; 109():106649. PubMed ID: 34271301
[TBL] [Abstract][Full Text] [Related]
2. Low dose triptolide reverses chemoresistance in adult acute lymphoblastic leukemia cells via reactive oxygen species generation and DNA damage response disruption.
Zhao H; Shi P; Deng M; Jiang Z; Li Y; Kannappan V; Wang W; Li P; Xu B
Oncotarget; 2016 Dec; 7(51):85515-85528. PubMed ID: 27888802
[TBL] [Abstract][Full Text] [Related]
3. BCL6 modulation of acute lymphoblastic leukemia response to chemotherapy.
Slone WL; Moses BS; Hare I; Evans R; Piktel D; Gibson LF
Oncotarget; 2016 Apr; 7(17):23439-53. PubMed ID: 27015556
[TBL] [Abstract][Full Text] [Related]
4. Inhibition of ubiquitin-specific protease 7 sensitizes acute myeloid leukemia to chemotherapy.
Cartel M; Mouchel PL; Gotanègre M; David L; Bertoli S; Mansat-De Mas V; Besson A; Sarry JE; Manenti S; Didier C
Leukemia; 2021 Feb; 35(2):417-432. PubMed ID: 32447346
[TBL] [Abstract][Full Text] [Related]
5. Romidepsin enhances the efficacy of cytarabine
Cheung LC; Cruickshank MN; Hughes AM; Singh S; Chua GA; Ford J; Ferrari E; Oommen J; Malinge S; Lock RB; Kees UR; Kotecha RS
Haematologica; 2019 Jul; 104(7):e300-e303. PubMed ID: 30679330
[No Abstract] [Full Text] [Related]
6. Combination Therapy for Treating Advanced Drug-Resistant Acute Lymphoblastic Leukemia.
Vicioso Y; Gram H; Beck R; Asthana A; Zhang K; Wong DP; Letterio J; Parameswaran R
Cancer Immunol Res; 2019 Jul; 7(7):1106-1119. PubMed ID: 31138521
[TBL] [Abstract][Full Text] [Related]
7. BACH2-mediated FOS confers cytarabine resistance via stromal microenvironment alterations in pediatric ALL.
Zhang H; Zhang R; Zheng X; Sun M; Fan J; Fang C; Tian X; Zheng H
Cancer Sci; 2021 Mar; 112(3):1235-1250. PubMed ID: 33393145
[TBL] [Abstract][Full Text] [Related]
8. A Novel cytarabine analog evokes synthetic lethality by targeting MK2 in p53-deficient cancer cells.
Song J; Yu J; Jeong LS; Lee SK
Cancer Lett; 2021 Jan; 497():54-65. PubMed ID: 33075425
[TBL] [Abstract][Full Text] [Related]
9. [Effects of bone marrow stromal cells on the chemotherapeutic sensitivity of acute lymphoblastic leukemia cells].
Wang Y; Han ZX; Zhang JC
Zhonghua Zhong Liu Za Zhi; 2017 Dec; 39(12):885-890. PubMed ID: 29262503
[No Abstract] [Full Text] [Related]
10. EVI-1 modulates leukemogenic potential and apoptosis sensitivity in human acute lymphoblastic leukemia.
Konantz M; André MC; Ebinger M; Grauer M; Wang H; Grzywna S; Rothfuss OC; Lehle S; Kustikova OS; Salih HR; Handgretinger R; Fend F; Baum C; Kanz L; Quintanilla-Martinez L; Schulze-Osthoff K; Essmann F; Lengerke C
Leukemia; 2013 Jan; 27(1):56-65. PubMed ID: 22828445
[TBL] [Abstract][Full Text] [Related]
11. Chidamide increases the sensitivity of refractory or relapsed acute myeloid leukemia cells to anthracyclines via regulation of the HDAC3 -AKT-P21-CDK2 signaling pathway.
Wang H; Liu YC; Zhu CY; Yan F; Wang MZ; Chen XS; Wang XK; Pang BX; Li YH; Liu DH; Gao CJ; Liu SJ; Dou LP
J Exp Clin Cancer Res; 2020 Dec; 39(1):278. PubMed ID: 33298132
[TBL] [Abstract][Full Text] [Related]
12. Promotion and maintenance of leukemia by ERG.
Tsuzuki S; Taguchi O; Seto M
Blood; 2011 Apr; 117(14):3858-68. PubMed ID: 21321361
[TBL] [Abstract][Full Text] [Related]
13. Activity of the multikinase inhibitor sorafenib in combination with cytarabine in acute myeloid leukemia.
Hu S; Niu H; Inaba H; Orwick S; Rose C; Panetta JC; Yang S; Pounds S; Fan Y; Calabrese C; Rehg JE; Campana D; Rubnitz JE; Baker SD
J Natl Cancer Inst; 2011 Jun; 103(11):893-905. PubMed ID: 21487100
[TBL] [Abstract][Full Text] [Related]
14. Small molecule XIAP inhibitors cooperate with TRAIL to induce apoptosis in childhood acute leukemia cells and overcome Bcl-2-mediated resistance.
Fakler M; Loeder S; Vogler M; Schneider K; Jeremias I; Debatin KM; Fulda S
Blood; 2009 Feb; 113(8):1710-22. PubMed ID: 19036706
[TBL] [Abstract][Full Text] [Related]
15. High cortactin expression in B-cell acute lymphoblastic leukemia is associated with increased transendothelial migration and bone marrow relapse.
Velázquez-Avila M; Balandrán JC; Ramírez-Ramírez D; Velázquez-Avila M; Sandoval A; Felipe-López A; Nava P; Alvarado-Moreno JA; Dozal D; Prieto-Chávez JL; Schaks M; Rottner K; Dorantes-Acosta E; López-Martínez B; Schnoor M; Pelayo R
Leukemia; 2019 Jun; 33(6):1337-1348. PubMed ID: 30573781
[TBL] [Abstract][Full Text] [Related]
16. Wnt pathway contributes to the protection by bone marrow stromal cells of acute lymphoblastic leukemia cells and is a potential therapeutic target.
Yang Y; Mallampati S; Sun B; Zhang J; Kim SB; Lee JS; Gong Y; Cai Z; Sun X
Cancer Lett; 2013 Jun; 333(1):9-17. PubMed ID: 23333798
[TBL] [Abstract][Full Text] [Related]
17. Tanshinone IIA enhances the inhibitory effect of imatinib on proliferation and motility of acute leukemia cell line TIB‑152 in vivo and in vitro by inhibiting the PI3K/AKT/mTOR signaling pathway.
Teng Z; Xu S; Lei Q
Oncol Rep; 2020 Feb; 43(2):503-515. PubMed ID: 31894340
[TBL] [Abstract][Full Text] [Related]
18. Synergism between the mTOR inhibitor rapamycin and FAK down-regulation in the treatment of acute lymphoblastic leukemia.
Shi PJ; Xu LH; Lin KY; Weng WJ; Fang JP
J Hematol Oncol; 2016 Feb; 9():12. PubMed ID: 26892465
[TBL] [Abstract][Full Text] [Related]
19. BET bromodomain inhibition targets both c-Myc and IL7R in high-risk acute lymphoblastic leukemia.
Ott CJ; Kopp N; Bird L; Paranal RM; Qi J; Bowman T; Rodig SJ; Kung AL; Bradner JE; Weinstock DM
Blood; 2012 Oct; 120(14):2843-52. PubMed ID: 22904298
[TBL] [Abstract][Full Text] [Related]
20. Leukemia propagating cells rebuild an evolving niche in response to therapy.
Duan CW; Shi J; Chen J; Wang B; Yu YH; Qin X; Zhou XC; Cai YJ; Li ZQ; Zhang F; Yin MZ; Tao Y; Mi JQ; Li LH; Enver T; Chen GQ; Hong DL
Cancer Cell; 2014 Jun; 25(6):778-93. PubMed ID: 24937459
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
